Journal Jam 7 – Amiodarone vs Lidocaine vs Placebo in Cardiac Arrest: The ALPS Trial

episode

Emergency Medicine Cases not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

recent transcribed audio

Nightcap Hour 1: Broncos WALK DOWN Rams + Ravens BEAT Cowboys in Brazil + Steelers STUN Bengals 57 min · 28 Sep 2026 · Nightcap

Day 271: Love of God (2026) 20 min · 28 Sep 2026 · The Catechism in a Year (with Fr. Mike Schmitz)

Day 271: The Sorrowful Mysteries 14 min · 28 Sep 2026 · The Rosary in a Year (with Fr. Mark-Mary Ames)

Nightcap Hour 2: Deshaun Watson WINS AGAIN + Justin Herbert PLAYING Like GARBAGE +Jaguars MAN HANDLE Patriots + Lions OUTLAST Jets + Colts SEND Texans PACKING + Commanders SHOCK Seahawks + Vikings CRUISE to WIN Over Bucs 1h 6m · 28 Sep 2026 · Club Shay Shay

Seventh Generation: Alan Newman and Jeffrey Hollender. A Partnership that Flourished—until it Failed. (2021) 1h 31m · 28 Sep 2026 · How I Built This with Guy Raz

Report any issue

Source

Recorded26 Jul 2016

Publisherfeeds.podcastmirror.com ↗

Handlerec:9163303

Show notes

Journal Jam 7 - Amiodarone vs Lidocaine vs Placebo in Cardiac Arrest: The ALPS Trial. In our most popular EM Cases episode to date - ACLS Guidelines Cardiac Arrest Controversies, we boldly stated, that there has never been an antiarrhythmic medication that has shown any long term survival benefit in cardiac arrest. The use of medications in cardiac arrest has been one of those things that we all do, but that we know the evidence isn’t great for. Yet Amiodarone is still in the newest AHA adult cardiac arrest algorithm for ventricular fibrillation or pulseless ventricular tachycarida – 300mg IV after the 3rd shock with the option to give it again at 150mg after that. Anti-arrhythmics have been shown in previous RCTs to increase the rate of return of spontaneous circulation and even increased survival to hospital admission, however none of them have been able to show a decrease in mortality or a favourable neurological outcome at hospital discharge. In other words, there has never been shown a long term survival or functional benefit - which is a bit disconcerting. But now, we have a recent large randomized, controlled trial that shines some new light on the role of anti-arrythmics in cardiac arrest - The ALPS trial: Amiodarone vs Lidocaine vs placebo in out of hospital cardiac arrest. In this Journal Jam podcast, Justin Morgenstern and Anton Helman interview two authors of the ALPS trial, Dr. Laurie Morrison a world-renowned researcher in cardiac arrest and Dr. Paul Dorian, a cardiac electrophysiologist and one of Canada's leading authorities on arrhythmias about what we should take away from the ALPS trial. It turns out, it's not so simple. We also discuss the value of dual shock therapy for shock resistant ventricular fibrillation and the future of cardiac arrest care.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related